Europital announces the official launching and certification attainment of its latest product.
Europital announces the official launching and certification attainment of its latest product. From January 2015 “Penthu®: The Future of Medical Management in Clinical Trials” will be available in the market.
Penthu® is an innovative and intuitive platform that drives performance, knowledge and efficiencies in clinical trials. This electronic tool allows project team to provide timely medical guidance and effficiently manage medical issues across multiple projects with minimal effort from the user’s side, thus reducing time, energy and resources while maximizing quality, knowledge and transparency.
This communication and knowledge trasnfer platform has been developed by clinical research professional and founded in three-core principles:
Thanks to an interactive environment that provides the kind of transparency needed to share and access information, the team’s performance is increased, creating real partnerships between project members.
Recently, PenThu® became an officially registered trademark in Europe. The European OHIM issued last November 2014 the Certificate of Registration for PenThu® as a Registered Trademark in the 28 member states of the European Union.
For more information about PenThu, visit www.pethu.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.